Keybank National Association OH trimmed its position in shares of Stryker Co. (NYSE:SYK) by 0.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 165,706 shares of the medical technology company’s stock after selling 579 shares during the period. Keybank National Association OH’s holdings in Stryker were worth $34,066,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Farmers National Bank bought a new stake in Stryker during the first quarter valued at about $25,000. Cable Hill Partners LLC bought a new stake in Stryker during the first quarter valued at about $30,000. RPG Investment Advisory LLC boosted its holdings in Stryker by 160.0% during the first quarter. RPG Investment Advisory LLC now owns 156 shares of the medical technology company’s stock valued at $31,000 after acquiring an additional 96 shares during the period. Horan Capital Advisors LLC. bought a new stake in Stryker during the first quarter valued at about $40,000. Finally, Webster Bank N. A. boosted its holdings in Stryker by 300.0% during the second quarter. Webster Bank N. A. now owns 200 shares of the medical technology company’s stock valued at $41,000 after acquiring an additional 150 shares during the period. Institutional investors own 73.48% of the company’s stock.

In related news, Director Allan C. Golston sold 3,399 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $209.84, for a total value of $713,246.16. Following the completion of the transaction, the director now owns 13,762 shares of the company’s stock, valued at $2,887,818.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Timothy J. Scannell sold 4,666 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $186.71, for a total transaction of $871,188.86. The disclosure for this sale can be found here. Insiders sold 20,097 shares of company stock valued at $4,045,678 in the last three months. Company insiders own 7.20% of the company’s stock.

NYSE:SYK traded down $6.33 during mid-day trading on Wednesday, hitting $212.78. The company’s stock had a trading volume of 25,050 shares, compared to its average volume of 1,243,368. Stryker Co. has a fifty-two week low of $144.75 and a fifty-two week high of $222.59. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.07 and a quick ratio of 1.26. The firm has a market cap of $81.66 billion, a P/E ratio of 29.35, a price-to-earnings-growth ratio of 2.66 and a beta of 0.85. The company has a fifty day simple moving average of $210.04.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 25th. The medical technology company reported $1.98 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.93 by $0.05. Stryker had a net margin of 24.99% and a return on equity of 25.98%. The firm had revenue of $3.65 billion during the quarter, compared to analyst estimates of $3.60 billion. During the same quarter in the prior year, the business posted $1.76 earnings per share. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. Sell-side analysts expect that Stryker Co. will post 8.2 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 0.98%. The ex-dividend date is Friday, September 27th. Stryker’s dividend payout ratio (DPR) is presently 28.45%.

SYK has been the subject of a number of research analyst reports. Wells Fargo & Co upped their price objective on shares of Stryker from $219.00 to $228.00 and gave the company an “outperform” rating in a research report on Tuesday, July 2nd. Svb Leerink reaffirmed an “outperform” rating on shares of Stryker in a research report on Wednesday, July 10th. BTIG Research reaffirmed a “buy” rating and set a $228.00 price objective on shares of Stryker in a research report on Monday, July 29th. Robert W. Baird upped their price objective on shares of Stryker from $206.00 to $239.00 and gave the company an “outperform” rating in a research report on Friday, July 26th. Finally, ValuEngine raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Five investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $214.89.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Read More: Special Dividends

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.